MuST AKT Program for Kidney Transplant
(MuST AKT Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the MuST AKT treatment for kidney transplant patients?
The Akt pathway, which is targeted by the MuST AKT treatment, is known to play a crucial role in cell survival and proliferation, and has been a focus in cancer therapy due to its involvement in cell growth and protection from cell death. This suggests that targeting Akt could potentially help in managing conditions that require cell survival and growth, such as in kidney transplants.12345
Is the MuST AKT treatment generally safe for humans?
How does the MuST AKT drug differ from other treatments for kidney transplant patients?
The MuST AKT drug may target the Akt signaling pathway, which is involved in cell survival and inflammation, potentially offering a novel approach compared to traditional immunosuppressive drugs like rapamycin that inhibit this pathway and are associated with prolonged delayed graft function.1112131415
What is the purpose of this trial?
For people living with kidney failure, the two active treatment options are dialysis or kidney transplantation. Transplantation is optimal, and especially from a living donor - offering patients longer survival, a better quality of life, and cost savings for the health system when compared to dialysis. However, 20% of patients die on dialysis while waiting for a deceased donor organ. As the rate of kidney failure continues to rise, the gap between demand and supply of the organs for transplantation increases.Compared to other provinces in Canada, the rate of living kidney donor transplantation is lower in Alberta, so it is essential that improvements are made to the process around living kidney donor transplantation, for better patient outcomes and care.Our published evidence-based review on strategies to increase living kidney donation, found that for patients with kidney failure, the intervention with the greatest health impact was personalized support, provided by a multidisciplinary team, to inform and educate the patients' social network. A province-wide survey also confirmed that many patients with kidney failure are unable to find a living kidney donor and also find it difficult to approach potential donors due to lack of skills, supports, and resources.The investigators have developed the Multidisciplinary Support To Access living donor Kidney Transplant (MuST AKT) intervention to support potential kidney transplant recipients find living donors through their social networks, and thereby increase the number of living kidney donor transplants in Alberta. The investigators will test the effectiveness of this intervention.
Research Team
Dr. Shojai
Principal Investigator
University of Alberta
Eligibility Criteria
This trial is for English-speaking individuals with kidney failure who have completed a 'kidney transplant introduction' module and are eligible for a transplant. It's not open to those who already have a donor, have had previous transplants, need multiple organ transplants, or score low on certain psychosocial or literacy tests.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants receive the MuST AKT intervention, a multidisciplinary, tailored person-centered intervention aimed to support participants in identifying potential donors and communicating with their social network.
Follow-up
Participants are monitored for kidney transplant status and other outcomes post-intervention.
Treatment Details
Interventions
- MuST AKT
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alberta
Lead Sponsor
Alberta Innovates Health Solutions
Collaborator